Gene therapy (GT) for adenosine deaminase-deficient severe combined immune deficiency (ADA-SCID) can provide significant long-term benefit when patients are given non-myeloablative conditioning and ADA enzyme replacement therapy (ERT) is withheld prior to autologous transplantation of gamma-retroviral vector-transduced bone marrow CD34+ cells. To determine the contributions of conditioning and discontinuation of ERT to the therapeutic effects, we analyzed these factors in Ada gene knock-out mice (Ada-/-). Mice were transplanted with ADA-deficient marrow transduced with an ADA-expressing gamma-retroviral vector without pre-conditioning or after 200cGy or 900cGy total-body irradiation and evaluated after 4 months. In all tissues analyzed, vector copy numbers (VCN) were 100-1,000-fold higher in mice receiving 900cGy compared to 200cGy (p-value<0.05). In mice receiving 200cGy, VCN was similar whether ERT was stopped or given for one or four months following GT. In non-conditioned mice, there was decreased survival with and without ERT, and VCN was very low to undetectable. When recipients were conditioned with 200cGy and received transduced lineage-depleted marrow, only recipients receiving ERT (1 month or 4) had detectable vector sequences in thymocytes. In conclusion, cytoreduction is important for engraftment of gene-transduced HSC and short-term ERT after GT did not diminish the capacity of gene-corrected cells to engraft and persist.
Introduction
In humans, adenosine deaminase (ADA) deficiency results in a severe combined immunodeficiency (SCID), and if left untreated, results in infant mortality (1) . ADA is responsible for deamination of adenosine (Ado) and 2'-deoxyadenosine (dAdo) to form inosine and 2'deoxyinosine, respectively, and is essential to purine salvage. Without ADA, Ado and dAdo both accumulate; however, it is primarily the accumulation of dAdo and subsequent dATP formation that cause the cytotoxicity in immature T lymphocytes (2) . The preferred treatment for ADA-deficient SCID (ADA-SCID) is hematopoietic stem cell transplantation (HSCT) with a matched sibling donor.
Transplants for ADA-SCID using matched-unrelated, or haplo-identical donors have lower survival (3) . When a suitable donor is not available or the patient is too ill for transplantation, the patient may be started on enzyme replacement therapy (ERT) with pegylated bovine ADA (Adagen®, Sigma Tau, Gaithersburg, MD). ERT does increase lymphocyte counts and immune function; however, absolute lymphocyte counts remain below normal and immune function decreases over time (4, 5) .
Since the current clinical options are suboptimal, ADA-deficient SCID is an ideal candidate for gene therapy approaches. It has been hypothesized that correction of a few autologous hematopoietic stem cells (HSCs) could result in corrected T-cell progeny that would have a strong selective advantage and would eventually fill the T-cell compartment (6) . The selective advantage of corrected T-cells in ADA-SCID has been observed in patients that had a spontaneous reversion of the mutation in one T-cell precursor where, over time, the T-cell compartment was entirely comprised of corrected T-cell progeny (7, 8) .
The earliest gene therapy (GT) clinical trials for ADA deficiency used murine gamma-retroviral vectors to transduce peripheral blood T lymphocytes and bone marrow (9, 10) , CD34+ isolated from For personal use only. on October 31, 2017. by guest www.bloodjournal.org From bone marrow (11) and from cord blood (12) . In these studies, patients were not given cytoreductive conditioning prior to receiving transduced cells and all patients remained on ERT.
These approaches did not provide clinical benefit and the frequency of gene-marked peripheral blood (PB) cells remained very low. However, in some studies, the frequency of gene-corrected PB T-cells increased when the ERT dose was either decreased or discontinued (13, 14) . It was hypothesized that the survival advantage of gene-corrected cells was blunted by the ERT. Longterm follow-up studies have indicated gene-corrected cells can persists for more than 10 years, contain different vector integration sites and are not the result of insertional oligoclonal expansion (15, 16) . In a later trial with improved gamma-retroviral vectors and transduction conditions, unconditioned patients remaining on ERT did not have clinical benefit (17) . In 2002, investigators in Milan reported that cytoreductive conditioning with a moderate dose of busulfan chemotherapy prior to re-infusion of transduced cells and cessation of ERT, resulted in multi-lineage engraftment of transduced cells and immune reconstitution (18) . ADA activity was detected across lineages, which was associated with a decrease in adenine metabolites. A later publication analyzed the long-term follow-up (1.8-10y) of 10 patients treated with this approach, and showed significant, long-term, clinical benefit (19) . Since then, groups in the UK and the US have demonstrated efficacy with this approach as well (20) (21) (22) .
Although GT for ADA-SCID has met success with clinical benefit for many patients (~70%), a number of patients in the ongoing clinical trials have experienced events that necessitated the restarting of ERT (19, 20, 21) , suggesting there could be improvements in outcomes. Thus, the primary goal of this study was to delimit the roles of ERT and cytoreductive conditioning in gene therapy ex vivo for ADA-SCID, using the ADA-deficient mouse and a gamma-retroviral vector currently being evaluated in a clinical gene therapy trial. We also investigated the efficacy of a short-term course of ERT post-GT to enhance engraftment of transduced cells. The results of For personal use only. on October 31, 2017. by guest www.bloodjournal.org From these experiments clearly demonstrate the importance of cytoreductive conditioning and the potential to enhance thymic engraftment with short-term ERT following gamma-retroviral mediated gene therapy for the clinical treatment of ADA-SCID.
Materials and Methods
Vector, Packaging and Stability. The gamma-retroviral vector, MND-MFG-huAda (MMA), based on the murine leukemia virus (MMLV) retrovirus, as was modified using the MND LTR enhancer/promoter to drive expression of the human Ada cDNA and includes the splice acceptor site from the 5' untranslated region of MMLV envelope gene (env)(23-25). The ATG transcription start site (TSS) of the human Ada cDNA is aligned at the ATG TSS of env to enhance transgene expression ( Figure 1A )(26). MMA was packaged by transient transfection in 293T human embryonic kidney cells in D10 for 10-14d (D10-Dulbecco's Modified Essential Medium, 10% FCS, 100U penicillin/streptomycin), and pseudotyped with vesicular stomatitis virus capsid protein (VSV-G). MMA/VSV-G was used to transduce GP+E+86 (GPE) cells (27) and repackage the vector with the murine ecotropic ENV protein. Cellular GPE clones were made by limited dilution of the transduced pool. Titer was determined on NIH-3T3 fibroblasts and a producer clone was based on the amount of ADA enzyme activity (~120 U/mg/min).
Mice.
A two-stage murine model of ADA-deficient SCID was generated and described previously (FVB;129-Ada tm1Mw Tg(PLADA)4118Rkmb/J; Jackson Laboratories, Bar Harbor, MA)(28,29). ERT was administered by weekly intramuscular injection of 250U/kg of ADAGEN® (Sigma Tau, Pharmaceuticals, Gaithersburg, MD). Mice were housed in accordance with IACUC (Saban
Research Institute at Childrens Hospital Los Angeles) and the National Institutes of Health
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From 6 guidelines. All animals were handled in laminar flow hoods and housed in micro-insulator cages in a pathogen-free colony.
Bone Marrow Harvest, Lineage-Depletion and HSCT.
Ada-/-donor mice (8-10wk) were euthanized and marrow was harvested from the femur, tibia, and humeral bones, pooled and, centrifuged for 10min at 400xg at 10 o C. Pooled marrow was plated on fibronectin-fragment CH-296 (20 mg/ml; Retronectin, Takara BIO, Inc., Otsu Japan) coated plates at 1x10^6 cells/ml in basal bone marrow media (BBMM: Iscove's Modified Dulbecco's Medium supplemented with 30% fetal calf serum (FCS), 1% bovine serum albumin (BSA; Stem Cell Technologies, Vancouver, Canada), 100uM 2-β-mercaptoethanol, 2mM glutamine, 100U/ml penicillin/streptomycin) freshly supplemented with murine cytokines (IL-3: 10ng/ml; IL-6: 25ng/ml, c-kit ligand: 2.5ng/ml; Biosource International, Inc., Camarillo CA) and cultured at 37 o C for 48 hours pre-stimulation.
Pooled marrow cells were lineage-depleted using anti-murine, biotin-conjugated, antibodies: CD5, CD45R (B220), CD11b, Anti-Gr-1 (Ly-6G/C, 7-4 and Ter-119) according to the manufacturer's instructions (Murine Lineage Depletion Kit, Miltenyi Biotec, Auburn, CA). Lineage-depleted cells (lin-) were re-suspended in BBMM at 1x10^6 cells/ml and plated, as described above, for prestimulation for 48 hours. Congenic (Ada+/+) female donor mice (8-10wk) were used as controls for transplant of fully ADA-replete marrow, with 5x10^6 unprocessed marrow cells suspended in injectable normal saline (USP; APP, Schaumburg, IL) injected via tail vein into male Ada-/-mice (8-10wk) (30) . Fragments of thymus, spleen, and liver were fixed and the left lung was perfused and fixed with 2% para-formaldehyde. Immunohistochemistry was performed as described using anti-human ADA monoclonal antibody (N-19; Santa Cruz Biotechnology, Santa Cruz, CA) (31) .
Immunophenotype and Function Assays. All immunophenotype and functional assays were performed as previously described (30, 32) . Single cell suspensions were made from thymus, Engraftment. The TSYR gene, located on the Y chromosome, was used to determine the amount of chimerism or engraftment in sex-mismatched transplants. To quantify the percentage of male DNA, qPCR was performed using a standard curve constructed from male murine tail DNA diluted into female murine tail DNA to form mixtures between 0.3-100% male DNA (33) .
ADA Enzyme Activity and Substrate Concentration in Tissues.
Tissues were harvested as parts of whole organs and flash frozen and store at -80C until processed. ADA enzyme assay was performed as described (29). Perchloric acid was used to extract adenine nucleosides from frozen For personal use only. on October 31, 2017. by guest www.bloodjournal.org From tissue, and adenosine (Ado) and deoxyadenosine (dAdo) were separated and quantified using reversed-phase high-pressure liquid chromatography as described (34) . 
Results
In mice, ADA-deficiency results in profound multi-system defects, including severe combined immunodeficiency (SCID). If untreated, Ada-/-pups succumb to a non-infectious, pulmonary insufficiency by postnatal d20; thus, survival after gene therapy (GT) is a potent test for efficacy. In a series of sequential experiments, bone marrow from Ada-/-mice was transduced ex vivo with the MMA gamma-retroviral vector and transplanted into syngeneic Ada-/-recipients. The first study assessed the role of cytoreduction prior to GT and the role of ERT after GT, the second study assessed efficacy of a short-term course of ERT after GT compared to a long-term course, and the third study assessed differences between transplanting transduced whole marrow (wm) compared to transduced lineage-depleted (lin-) marrow cells, with and without mild cytoreductive conditioning and/or ERT. 
Study 1. Cytoreductive Conditioning and ERT Cessation

Study 2. Long Course ERT and Short Course ERT
Study 3. Cytoreduction, ERT and Target Cell.
In Studies 1 and 2, whole bone marrow was transduced and infused into recipients. However, in the clinical setting, patients are infused with transduced autologous CD34+ marrow cells, a population enriched ~50-fold for human HSC. The following study was designed to simulate conditions closer to approaches used in current clinical trials for ADA-SCID. While the CD34 marker is not useful for enrichment of murine HSC, lineage-depleted murine bone marrow cell preparations are similarly enriched ~50-fold for murine HSC. Ada-/-mice were conditioned with 0cGy (0) or 200cGy (200) TBI, and transplanted with either transduced whole marrow (wm) or 13 transduced lineage-depleted bone marrow (lin-), and maintained on ERT for 4m (+4mERT), 1m (+1mERT) or ERT was stopped after GT (-NoERT).
Survival. Unlike ADA-deficient patients, survival can be used as a measure of efficacy (engraftment of gene-marked HSC) in the Ada-/-mice, since ADA-deficiency is a lethal condition unrelated to the SCID phenotype. Overall, mice conditioned with 200cGy TBI had higher survival than non-conditioned mice, regardless of transduced cell type (wm or lin-) or ERT course of treatment (p-values<0.01)( Figure 6A ). When non-conditioned mice were not maintained on ERT, survival was significantly reduced compared to non-conditioned mice that were maintained on a short course of ERT (p-values<0.01)( Figure 6B ). In the condition closest to current clinical gene therapy protocols for ADA-SCID (non-myeloablative conditioning and no ERT), survival was also significantly reduced in mice conditioned with 200cGy and transplanted with lineage-depleted marrow and not maintained on ERT compared to mice maintained on ERT for 1 or 4 months (p-values<0.01). As seen previously, for mice conditioned with 200cGy and transplanted with whole marrow, there were no differences in survival with or without ERT.
Marking. . Overall, mice receiving transduced whole marrow had 10-100x higher bone marrow VCN compared to mice receiving lineage-depleted marrow regardless of ERT course (p-values<0.05) ( Figure 6C ). For most tissues analyzed, ERT did not affect VCN or numbers of gene- 
Discussion
Initial gene therapy trials for ADA-deficient SCID patients used enriched populations of bone marrow CD34+ cells, and patients were not given cytoreductive conditioning and they remained on ERT (10) (11) (12) (13) . These studies did not demonstrate clinical efficacy, as the frequency of gene-corrected cells was low. It was hypothesized that omission of cytoreductive marrow conditioning limited HSC engraftment and the continuous administration of ERT blunted any selective survival advantage the corrected lymphocytes may have had over the uncorrected cells. Thus, in subsequent clinical trials, patients are being treated with nonmyeloablative doses of busulfan or melphalan and ERT is discontinued prior to re-infusion of the autologous, transduced CD34+ cells (14, (19) (20) (21) (22) . The premises for these protocol changes were two-fold: cytoreductive conditioning would 'make space' in the marrow compartment and For personal use only. on October 31, 2017. by guest www.bloodjournal.org From ERT cessation would allow the transduced, corrected lymphocytes to realize their survival advantage. This approach has resulted in a high frequency of gene-marked cells, especially in the T-cell compartment, and has had a clear clinical benefit for the majority of patients (19, 22) . However, despite the clinical benefits achieved, it was not possible to determine the individual roles of cytoreduction and ERT, as both changes were implemented together. While both factors may add to efficacy, they also add to potential risks, from chemotherapy-related toxicities and from an increased risk of infection due to lymphopenia that occurs following ERT withdrawal. In one study, ADA-deficient SCID patients receiving HSC GT, with ERT cessation, but without conditioning, had delayed immune reconstitution (39) , supporting the role for cytoreduction. As gene therapy becomes a standard of care for ADA-deficient SCID, it will be important to understand the roles of conditioning, with enhanced engraftment of transduced HSC, and the cessation of ERT, with increased selective advantage for gene-corrected cells for achieving best clinical outcomes. We explored these two issues in gene transfer/BMT studies in ADA gene knock-out mice.
Cytoreductive Conditioning. ADA-deficient mice die postnatal d20-21 unless treated with ERT, HSCT or GT. If treatment is discontinued (ERT; less than 14 days) or ineffective (HSCT/GT) the adult mice will eventually die of pulmonary insufficiency, (pathogen-free housing), thus survival can be a measure of efficacy of a treatment. In our studies, higher intensity conditioning consistently led to higher levels of gene-marked cells in lymphoid and non-lymphoid organs. Mice receiving 900cGy always had higher VCN (10-1000 fold) in the thymus, spleen, marrow, lung and liver than mice receiving 200cGy, regardless of whether ERT was continued or not. Also, the absolute numbers of gene-marked cells in the thymus and spleen were 100-1000 fold higher in the 900cGy mice compared to the 200cGy mice.
Furthermore, mice not conditioned (0cGy), had poor survival without short (1m) or long (4m)
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From term ERT and VCN was dramatically reduced. These results indicate that the TBI dose of cytoreductive conditioning is critical for determining the amount of engraftment and expansion of transduced HSC and progenitors, as has been shown in other murine models of gene therapy (40). Similarly, in clinical trials of gene therapy for ADA-deficient SCID, patients with the longest period of neutropenia following conditioning with busulfan had the highest frequency of gene-marked cells (19) and when two protocols were used, one with and without busulfan, marking is greatly improved with busulfan (21). It is important to note that radiation is not equivalent to busulfan, and that the possible effects of radiation should be considered when interpreting these results. Mice receiving 900cGy did have lower total numbers of immature and mature lymphocytes than those receiving 200cGy, suggesting that the higher dose of radiation may damage the lymphoid organ stroma and impair immune reconstitution (41).
ERT.
In the early clinical trials, ERT was reduced in a few patients at various times after GT and this resulted in an increase in the measured frequency of gene-marked cells in peripheral blood T lymphocytes (13, 14) . In one ADA-deficient patient who experienced a spontaneous reversion of a mutant Ada allele in a progenitor cell, ADA-replete T-cells that arose were obscured when the patient resumed ERT (42). From these results, it was hypothesized that continued ERT may blunt the selective advantage of the gene-corrected cells, resulting in a lower number of corrected cells and vector sequence detection (43). However, when only the average VCN is measured (e.g. qPCR for vector sequence in tissue DNA), it would be difficult to distinguish between a decrease in vector detection from reduced selective pressure from a decrease in VCN from dilution of vector sequence by the increased amount of un-corrected cell DNA. Therefore, to understand if there is a true diminution of the absolute numbers of genecorrected cells, we calculated the absolute number of gene-marked cells in tissues when ADAdeficient mice remained on ERT or not. It is of interest that we found no difference in the For personal use only. on October 31, 2017. by guest www.bloodjournal.org From absolute numbers of gene-marked cells in any analyzed tissue when mice received 900cGy prior to receiving transduced whole marrow cells, with or without ERT. Likewise, we found no difference in the absolute numbers of gene-marked lymphocytes from mice receiving cytoreduction with 200cGy, with or without ERT, despite increases in the absolute numbers of lymphocytes with ERT and apparent dilution of vector sequences in gene-corrected cell DNA by uncorrected cell DNA. Likewise, a few subjects in ADA gene therapy clinical trials have been restarted on ERT after GT and PBMC DNA VCN did not decrease (19) (20) (21) (22) . Thus, it could be argued that the frequency/survival of gene-corrected cells actually increased on ERT since VCN remained the same despite the putative dilution of vector sequence with continued ERT.
We cannot say for sure how ERT improves survival of gene-corrected cells, but we hypothesize ERT may augment the ADA supplied by the gene-corrected thymocytes by providing a good 'soil' for thymopoiesis to further expand the T-cell population since it has been shown that CD4-CD8-thymocyte differentiation is disrupted and apoptosis is initiated when ADA substrates accumulate in ADA-deficient fetal thymic organ culture (44). Study 3 also supports this hypothesis. When mice received lineage-depleted marrow with 200cGy and no ERT (the closest condition to current clinical trial approaches), vector sequences were only detected in the thymus when mice remained on ERT for 1 or 4m. Likewise, transduced whole marrow will also contain many types of transduced cells expressing ADA, albeit not all are transduced with 2 copies/cell as in HSCT. We hypothesize that many transduced cells will not achieve long-term engraftment, but could provide ADA for detoxification of the niche, as well as transduced stromal cells that may be important for HSC localization within the For personal use only. on October 31, 2017. by guest www.bloodjournal.org From bone marrow niche and other tissues. Unexpectedly, we found VCN was higher in liver and lung from recipients of transduced whole marrow compared to lineage-depleted marrow cells, regardless of ERT treatment. Both lung and liver exhibit significant pathology in the ADA-deficient mouse and transduced whole marrow may have other hematopoietic and mesenchymal cells that facilitate "liver/lung engraftment" (45). Although it is not clear how relevant this observation is to the human experience, a recent study showed that many ADA-deficient patients, unlike X-linked SCID patients, presented with lung pathology not associated with an infectious agent and with histopathology similar to that observed in ADA-deficient mice (46).
Whole Marrow vs. Lineage-depleted Marrow. Mice transplanted with transduced whole marrow
Although the mechanism for improved engraftment is not fully elucidated, these studies suggest early ADA expression from transduced whole marrow or from exogenously supplied ERT combined with transduced lineage-depleted marrow cells, may act to enhance the marrow and thymic micro- For personal use only. on October 31, 2017. by guest www.bloodjournal.org From
